Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice

Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice

Lipid metabolism disorders contribute to hyperlipidemia and hepatic steatosis. It is ideal to develop drugs simultaneous improving both hyperlipidemia and hepatic steatosis. Nitazoxanide is an FDA-approved oral antiprotozoal drug with excellent pharmacokinetic and safety profile. We found that nitaz...

Full description

Bibliographic Details
Main Authors: Fengfeng Li, Man Jiang, Minghui Ma, Xuyang Chen, Yidan Zhang, Yixin Zhang, Yuanyuan Yu, Yunfeng Cui, Jiahui Chen, Hui Zhao, Zhijie Sun, Deli Dong
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Nitazoxanide
Tizoxanide
Hyperlipidemia
Hepatic steatosis
AMPK
Autophagy
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383521003518

Internet

http://www.sciencedirect.com/science/article/pii/S2211383521003518

Similar Items